CD89 Recombinant antibody

CD89 Recombinant Antibody for WB, ELISA
Cat No. 84384-5-RR

产品说明书

CloneNo. 241426H1

宿主/亚型

Rabbit / IgG

种属反应性

human

应用

WB, ELISA

IgA Fc receptor, FCAR, 241426H1

缓冲液配方:  PBS and Azide
PBS and Azide
PBS Only
偶联物:  Unconjugated
Unconjugated
规格: 

-/ -


经过测试的应用

Positive WB detected inA549 cells, HL-60 cells, K-562 cells, U-937 cells, Jurkat cells

推荐稀释比

应用推荐稀释比
Western Blot (WB)WB : 1:1000-1:8000
It is recommended that this reagent should be titrated in each testing system to obtain optimal results.
Sample-dependent, Check data in validation data gallery.

产品信息

84384-5-RR targets CD89 in WB, ELISA applications and shows reactivity with human samples.

经测试应用 WB, ELISA Application Description
经测试反应性 human
免疫原 Recombinant Protein 种属同源性预测
宿主/亚型 Rabbit / IgG
抗体类别 Recombinant
产品类型 Antibody
全称 Fc fragment of IgA, receptor for
别名 IgA Fc receptor, FCAR, 241426H1
计算分子量 287 aa, 32 kDa
观测分子量65-70 kDa
GenBank蛋白编号BC027953
基因名称 CD89
Gene ID (NCBI) 2204
RRIDAB_3671920
偶联类型 Unconjugated
形式 Liquid
纯化方式Protein A purfication
UNIPROT IDP24071
储存缓冲液 PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
储存条件Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

背景介绍

FcαRI (CD89) is a member of the Fc receptor immunoglobulin superfamily, constitutively expressed on cells of the myeloid lineage like neutrophils, eosinophils, monocytes macrophages, and platelets (PMID: 28103138). CD89 expression and activation are increased in human blood phagocytes following bacterial infection, together with increased expression and association of FcRγ with CD89 (PMID: 34756952). CD89 binds both subclasses of IgA (IgA1 and IgA2) with moderate affinity, but also binds other molecules such as TfR1, C-reactive protein and bacterial ligands. CD89 represents an effective target molecule for immunotherapy mediated by bispecific antibodies (PMID: 37081893).

实验方案

Product Specific Protocols
WB protocol for CD89 antibody 84384-5-RRDownload protocol
Standard Protocols
Click here to view our Standard Protocols
Loading...